News & Updates

Show Multimedia Only

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

24 Jul 2025 by

A post-hoc analysis of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC) has found that while durvalumab demonstrated an overall survival (OS) benefit vs placebo irrespective of immune-mediated adverse events (imAEs), the improvement in OS was numerically greater among patients who experienced imAEs.

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

24 Jul 2025

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

24 Jul 2025 by

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) in East Asian patients with persistent, recurrent or metastatic cervical cancer, according to an exploratory analysis of the final results from the phase III KEYNOTE-826 trial.

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

24 Jul 2025

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025 by

Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

New drug applications approved by US FDA as of 1-15 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

High-fat dairy ups risk of liver disease mortality, cancer

21 Jul 2025

Individuals who regularly consume high-fat dairy are at greater risk of death due to chronic liver diseases (CLD), reveals a recent study. However, low-fat dairy intake may lower such risk.

High-fat dairy ups risk of liver disease mortality, cancer

21 Jul 2025

Infection-related deaths not uncommon among cancer survivors

18 Jul 2025

Many patients living with cancer die of infection, and early identification of those at risk is important to prevent infection-related mortality, according to a study.

Infection-related deaths not uncommon among cancer survivors

18 Jul 2025

Social media posts show difficulties faced by sarcoma patients

17 Jul 2025

An analysis of social media posts reveals the interconnected challenges that patients with sarcoma have to go through, including treatment decisions, financial concerns, and work impact.

Social media posts show difficulties faced by sarcoma patients

17 Jul 2025

Subcutaneous on par with IV pembrolizumab for NSCLC

17 Jul 2025 by

Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.

Subcutaneous on par with IV pembrolizumab for NSCLC

17 Jul 2025

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

17 Jul 2025

Combination treatment with bevacizumab plus erlotinib appears to work against hereditary leiomyomatosis and renal-cell cancer (HLRCC)-associated or sporadic papillary renal-cell carcinoma, according to an open-label phase II study.

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

17 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

COVID-19 booster shots confer protection against severe disease in cancer patients

COVID-19 booster shots confer protection against severe disease in cancer patients

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

Original New Drug Application Approvals by US FDA (16-30 June 2025)

High-fat dairy ups risk of liver disease mortality, cancer

High-fat dairy ups risk of liver disease mortality, cancer

Infection-related deaths not uncommon among cancer survivors

Infection-related deaths not uncommon among cancer survivors

Social media posts show difficulties faced by sarcoma patients

Social media posts show difficulties faced by sarcoma patients

Subcutaneous on par with IV pembrolizumab for NSCLC

Subcutaneous on par with IV pembrolizumab for NSCLC

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer